Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Window of opportunity clinical trial designs to study cancer metabolism.

Journal article

Aroldi F. and Lord SR., (2019), British journal of cancer

Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer.

Journal article

Morotti M. et al, (2019), Proc Natl Acad Sci U S A, 116, 12452 - 12461

Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients.

Journal article

Morotti M. et al, (2018), Eur J Drug Metab Pharmacokinet, 43, 137 - 153

Fluciclovine is a potential imaging biomarker of glutamine utilisation in breast cancer

Conference paper

Teoh EJ. et al, (2017), EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 44, S633 - S634

Antiangiogenic Resistance and Cancer Metabolism: Opportunities for Synthetic Lethality.

Journal article

Lord S. et al, (2016), Curr Drug Targets, 17, 1714 - 1727

Early phase cancer clinical trials: design, ethics and future directions.

Journal article

Coupe N. et al, (2015), Br J Hosp Med (Lond), 76, 409 - 413

Neoadjuvant Window Studies of Metformin and Biomarker Development for Drugs Targeting Cancer Metabolism.

Journal article

Lord SR. et al, (2015), J Natl Cancer Inst Monogr, 2015, 81 - 86

Imaging tumour hypoxia with positron emission tomography.

Journal article

Fleming IN. et al, (2015), Br J Cancer, 112, 238 - 250

Gene expression and hypoxia in breast cancer.

Journal article

Favaro E. et al, (2011), Genome Med, 3

METFORMIN'S EFFECTS ON BREAST CANCER LIPID METABOLISM

Conference paper

Lord SR. et al, (2011), ANNALS OF ONCOLOGY, 22

Load More